Englander Institute for Precision Medicine

Publications

Found 692 results
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJasmine, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R et al..  2021.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.. Nat Med. 27(12):2200-2211.
B
Hajirasouliha I, Semrau S.  2023.  Back in 3D-a report on Genome Informatics 2022.. Genome Biol. 24(1):57.
Boeck N, Trajanoski Z, Galluzzi L.  2023.  Bacterial antigens unleash tumor-targeting immunity.. Cell Host Microbe. 31(12):1945-1947.
Toosi H, Moeini A, Hajirasouliha I.  2019.  BAMSE: Bayesian model selection for tumor phylogeny inference among multiple samples.. BMC Bioinformatics. 20(Suppl 11):282.
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard J-C, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J et al..  2021.  Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.. ESMO Open. 6(5):100241.
Yamazaki T, Galluzzi L.  2022.  BAX and BAK dynamics control mitochondrial DNA release during apoptosis.. Cell Death Differ. 29(6):1296-1298.
Madhukar NS, Khade PK, Huang L, Gayvert K, Galletti G, Stogniew M, Allen JE, Giannakakou P, Elemento O.  2019.  A Bayesian machine learning approach for drug target identification using diverse data types.. Nat Commun. 10(1):5221.
Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, Lehmann CHK, Pan H, Paulhan N, Amon L et al..  2023.  BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.. Cancer Discov. 13(11):2448-2469.
Shah Y, Kulm S, Nauseef JT, Chen Z, Elemento O, Kensler KH, Sharaf RN.  2024.  Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.. PLoS Comput Biol. 20(4):e1011990.
Cultrara C, Uhl C, Kirby K, Elrazaq EAbed, Zellander A, Andrews DW, Scott CB, Galluzzi L, Exley MA, Zilberberg J.  2023.  A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.. J Immunother Cancer. 11(8)
Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.
Meleshko D, Mohimani H, Tracanna V, Hajirasouliha I, Medema MH, Korobeynikov A, Pevzner PA.  2019.  BiosyntheticSPAdes: reconstructing biosynthetic gene clusters from assembly graphs.. Genome Res. 29(8):1352-1362.
Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A et al..  2023.  Bladder cancer organoids as a functional system to model different disease stages and therapy response.. Nat Commun. 14(1):2214.
Cho BAngela, Iyengar NM, Zhou XKathy, Morrow M, Giri DD, Verma A, Elemento O, Pollak M, Dannenberg AJ.  2021.  Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome.. Carcinogenesis. 42(10):1281-1292.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.
Choi S, Whitman MA, Shimpi AA, Sempertegui ND, Chiou AE, Druso JE, Verma A, Lux SC, Cheng Z, Paszek M et al..  2023.  Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.. Nat Biomed Eng. 7(11):1455-1472.
Santambrogio L, Marrack P.  2023.  The broad spectrum of pathogenic autoreactivity.. Nat Rev Immunol. 23(2):69-70.
Croker JA, Patel R, Campbell KS, Barton-Baxter M, Wallet S, Firestein GS, Kimberly RP, Elemento O.  2021.  Building biorepositories in the midst of a pandemic.. J Clin Transl Sci. 5(1):e92.
C
Marchi S, Giorgi C, Galluzzi L, Pinton P.  2020.  Ca Fluxes and Cancer.. Mol Cell. 78(6):1055-1069.
Dhaouadi N, Vitto VAngela Mar, Pinton P, Galluzzi L, Marchi S.  2023.  Ca signaling and cell death.. Cell Calcium. 113:102759.
Suzuki H, Castellano D, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Foster MC, Ozatilgan A, Geffriaud-Ricouard C et al..  2021.  Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.. Jpn J Clin Oncol. 51(8):1287-1297.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard J-C, Bamias A, Carles J et al..  2019.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.. N Engl J Med. 381(26):2506-2518.
Kasi PMurtaza.  2022.  Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.. Oncologist. 27(5):336-337.